JP2012530141A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530141A5
JP2012530141A5 JP2012516197A JP2012516197A JP2012530141A5 JP 2012530141 A5 JP2012530141 A5 JP 2012530141A5 JP 2012516197 A JP2012516197 A JP 2012516197A JP 2012516197 A JP2012516197 A JP 2012516197A JP 2012530141 A5 JP2012530141 A5 JP 2012530141A5
Authority
JP
Japan
Prior art keywords
dosage form
apixaban
released
controlled release
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530141A (ja
JP5775071B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038660 external-priority patent/WO2010147978A1/en
Publication of JP2012530141A publication Critical patent/JP2012530141A/ja
Publication of JP2012530141A5 publication Critical patent/JP2012530141A5/ja
Application granted granted Critical
Publication of JP5775071B2 publication Critical patent/JP5775071B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516197A 2009-06-16 2010-06-15 アピキサバンの製剤形 Active JP5775071B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18744209P 2009-06-16 2009-06-16
US61/187,442 2009-06-16
PCT/US2010/038660 WO2010147978A1 (en) 2009-06-16 2010-06-15 Dosage forms of apixaban

Publications (3)

Publication Number Publication Date
JP2012530141A JP2012530141A (ja) 2012-11-29
JP2012530141A5 true JP2012530141A5 (OSRAM) 2013-08-01
JP5775071B2 JP5775071B2 (ja) 2015-09-09

Family

ID=42677548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516197A Active JP5775071B2 (ja) 2009-06-16 2010-06-15 アピキサバンの製剤形

Country Status (24)

Country Link
US (4) US20120087978A1 (OSRAM)
EP (2) EP3520776A1 (OSRAM)
JP (1) JP5775071B2 (OSRAM)
KR (1) KR20120029428A (OSRAM)
CN (1) CN102802608A (OSRAM)
AU (1) AU2010260208B2 (OSRAM)
BR (1) BRPI1010739A2 (OSRAM)
CA (1) CA2765413A1 (OSRAM)
CY (1) CY1122685T1 (OSRAM)
DK (1) DK2442791T3 (OSRAM)
ES (1) ES2769357T3 (OSRAM)
HR (1) HRP20200297T1 (OSRAM)
HU (1) HUE048542T2 (OSRAM)
IL (1) IL216421A0 (OSRAM)
LT (1) LT2442791T (OSRAM)
MX (1) MX2011013080A (OSRAM)
PL (1) PL2442791T3 (OSRAM)
PT (1) PT2442791T (OSRAM)
RU (1) RU2012101214A (OSRAM)
SG (1) SG176785A1 (OSRAM)
SI (1) SI2442791T1 (OSRAM)
SM (1) SMT202000093T1 (OSRAM)
WO (1) WO2010147978A1 (OSRAM)
ZA (1) ZA201109334B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3251660T3 (pl) * 2010-02-25 2020-02-28 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacje apiksabanu
CA2830948A1 (en) * 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
EP2554159A1 (en) 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
WO2013164839A2 (en) * 2012-03-06 2013-11-07 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
WO2013175494A2 (en) * 2012-04-10 2013-11-28 Rubicon Research Private Limited Controlled release pharmaceutical formulations of direct thrombin inhibitors
US20150272891A1 (en) * 2012-05-24 2015-10-01 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP2900217A1 (en) 2012-09-26 2015-08-05 Bristol-Myers Squibb Company Apixaban liquid formulations
CN104721156B (zh) * 2013-12-18 2020-05-01 山东新时代药业有限公司 一种含利伐沙班的片剂
EP3086778A1 (en) * 2013-12-23 2016-11-02 Laboratorios Del. Dr. Esteve, S.A. Oral pharmaceutical composition
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN104971355B (zh) * 2014-04-02 2018-04-24 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
US20150335586A1 (en) 2014-05-20 2015-11-26 R.P. Scherer Technologies, Llc Capsule dispensing container
JP6359390B2 (ja) * 2014-09-05 2018-07-18 テルモ株式会社 インプラントデバイスおよびインプラントデバイス植え込み具
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106902115A (zh) * 2015-12-22 2017-06-30 江苏万邦生化医药股份有限公司 阿哌沙班在治疗糖尿病足药物中的应用
US10537524B2 (en) 2016-01-12 2020-01-21 North & South Brother Pharmacy Investment Company Limited Apixaban solid composition and preparation method thereof
CN106986868B (zh) * 2016-01-21 2020-04-21 广东东阳光药业有限公司 包含阿哌沙班的共晶体及其制备方法
US11154558B2 (en) * 2016-04-15 2021-10-26 Adams Pharmaceuticals LLC Prevention of atherosclerotic events with direct factor Xa inhibitors
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
EP3826609A4 (en) * 2018-02-21 2022-01-12 Blaesi, Aron H. Expanding structured dosage form
HRP20240529T1 (hr) 2018-04-16 2024-07-05 Bristol-Myers Squibb Company Formulacije apiksabana
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
EP3838265A4 (en) * 2018-08-14 2022-05-11 Jiangsu Hengrui Medicine Co., Ltd. INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
KR102045721B1 (ko) * 2019-03-27 2019-11-18 주식회사 씨트리 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구
KR102044676B1 (ko) * 2019-03-27 2019-11-14 주식회사 씨트리 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법
CN110037990B (zh) * 2019-04-15 2023-03-28 海正药业(杭州)有限公司 一种阿哌沙班固体无定形分散体的制备工艺
WO2020219384A1 (en) * 2019-04-26 2020-10-29 Taho Pharmaceuticals Ltd. Apixaban transdermal delivery system and uses thereof
WO2020231791A1 (en) * 2019-05-10 2020-11-19 Fordoz Pharma Corp. Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof
JP7752487B2 (ja) * 2020-03-24 2025-10-10 日本ジェネリック株式会社 アピキサバン含有固体分散体
JP7520351B2 (ja) * 2020-08-14 2024-07-23 日医工株式会社 アピキサバン含有医薬組成物
WO2022061149A1 (en) * 2020-09-18 2022-03-24 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022123074A1 (en) * 2020-12-13 2022-06-16 Dafechem Ltd Liquid apixaban formulation in small dose volume
BR112023025772A2 (pt) * 2021-06-08 2024-02-27 Taho Pharmaceuticals Ltd Produto de filme solúvel em água, e, método para tratamento de trombose ou de um distúrbio relacionado
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
US12213972B2 (en) * 2022-07-27 2025-02-04 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
WO2024144207A1 (en) * 2022-12-26 2024-07-04 Rexpharmtech Co., Ltd Sustained-release tablet comprising apixaban
AU2024256542A1 (en) * 2023-04-18 2025-10-23 Incyclix Bio, Llc Advantageous human dosage regimens for administration of inx-315
WO2024261686A1 (en) * 2023-06-23 2024-12-26 Ronak Patel A gastroretentive composition comprising apixaban

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4247498A (en) 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4564488A (en) 1978-07-31 1986-01-14 Akzo Nv Methods for the preparation of porous fibers and membranes
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US4490431A (en) 1982-11-03 1984-12-25 Akzona Incorporated 0.1 Micron rated polypropylene membrane and method for its preparation
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US5225192A (en) 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6492991B1 (en) 1998-08-28 2002-12-10 Ati International Srl Method and apparatus for controlling compressed Z information in a video graphics system
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
MXPA01006108A (es) 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
HUP0400263A2 (hu) 2001-06-21 2005-03-29 Pfizer Products Inc. Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
KR100759635B1 (ko) 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20030175346A1 (en) 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
KR20040083493A (ko) * 2002-02-01 2004-10-02 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형
WO2005011634A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
GB0417132D0 (en) 2004-07-31 2004-09-01 Koninkl Philips Electronics Nv A shift register circuit
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
CN101340933A (zh) * 2005-08-17 2009-01-07 百时美施贵宝公司 具有环糊精的因子xa抑制剂包合配合物
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20070259913A1 (en) * 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
TW200824723A (en) 2006-09-12 2008-06-16 Glaxo Group Ltd Pharmaceutical composition
US20110045028A1 (en) 2006-11-30 2011-02-24 Takeda Pharmaceutical Company Limited Sustained release preparation

Similar Documents

Publication Publication Date Title
JP2012530141A5 (OSRAM)
HRP20200297T1 (hr) Dozni oblici apiksabana
JP2015057451A5 (OSRAM)
CL2013000347A1 (es) Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
JP2010222367A5 (OSRAM)
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
NZ619857A (en) A fast dissolving pharmaceutical composition
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
JP2014218522A5 (OSRAM)
CN110035744A (zh) 一种尼拉帕尼缓控释药物组合物及其用途
JP2009280621A5 (OSRAM)
JP2013503165A5 (OSRAM)
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
NZ602441A (en) A fast dissolving pharmaceutical composition
AR083361A1 (es) Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
JP2014520871A5 (OSRAM)
JP2015510928A5 (OSRAM)
JP2019522037A5 (OSRAM)
JP2013534527A5 (OSRAM)
JP2012217972A5 (OSRAM)